Jump To


  • Generic Name: latanoprostene bunod ophthalmic solution
  • Brand Name: Vyzulta
Last updated on MDtodate: 10/8/2022


The following adverse reactions are described elsewhere in the labeling:

  • Pigmentation
  • Eyelash Changes
  • Intraocular Inflammation
  • Macular Edema
  • Bacterial Keratitis
  • Use with Contact Lens

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VYZULTA was evaluated in 811 patients in 2 controlled clinical trials of up to 12 months duration. The most common ocular adverse reactions observed in patients treated with latanoprostene bunod were: conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Approximately 0.6% of patients discontinued therapy due to ocular adverse reactions including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, vision blurred, punctate keratitis and foreign body sensation.



Read Next Article

PHP Code Snippets Powered By : XYZScripts.com